Neurocognition as a biomarker in the rare autonomic disorders of CCHS and ROHHAD.
Frank A ZelkoRemi Z WelbelCasey M RandTracey StewartAllaa Fadl-AllaIlya KhaytinSusan M SlatteryDebra E Weese-MayerPublished in: Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2022)
Neurocognitive monitoring is recommended as a component of routine clinical care in CCHS and ROHHAD as a marker of disease status and to ensure that educational support and disability accommodations are provided as early as possible. Collaborative efforts will be essential to obtain samples needed to enhance our understanding of neurocognitive outcomes in CCHS and ROHHAD.